Impact of date palm pollen (*Phoenix dactylifera*) treatment on paracetamol-induced hepatorenal toxicity in rats

Abdulrahman Khazim Al-Asmari¹*, Mansour S. Al-Said², Rajamohamed Abbasmanthiri¹, Ahmed Al-Buraidi³, Khalid Elfaki Ibrahim⁴ and Syed Rafatullah¹

Abstract

**Background:** Consumption of plant-derived nutraceuticals and crude drugs in Arab traditional medicine is widely believed to confer beneficial effects in liver and kidney diseases. Fruits from the date palm *Phoenix dactylifera* L. are a rich source of nutrients and bioactive phytochemicals which possess a myriad of pharmacological effects. Herein, we examined the impact of Date Palm Pollen (DPP) aqueous suspension treatment on paracetamol (APAP) [Acetaminophen (APAP)] triggered hepatorenal damage in rats and further explored the underlying putative mechanism.

**Methods:** Thirty Wistar rats were assigned to five groups (n = 6/group). Group I was control group; animals in group II were administered APAP 1000 mg/kg body weight (b.w.) intraperitoneally (i.p.); Group III and IV administered APAP plus date palm pollen with doses of 50, 100 mg/kg b.w and group V were administered APAP plus Silymarin (SIL) 10 mg/kg b.w. (i.p) respectively. Various biochemical parameters and histological assessment were evaluated in serum and tissue homogenate.

**Results:** Pretreatment with DPP aqueous suspensions (50 and 100 mg/kg b.w.) significantly (p < 0.05) thwarted APAP triggered alterations in serum biomarkers of liver damage [aspartate transaminase (AST), alanine aminotransferase (ALT), γ-glutamyl transferase (GGT) and alkaline phosphatase (ALP)], serum albumin as well as bilirubin. DPP treatment further mitigated APAP triggered dyslipidemia associated with hepatic damage by influencing APAP elicited changes in serum levels of cholesterol, triglycerides, HDL, LDL and VLDL. DPP treatment significantly (p < 0.05) ameliorated extrahepatic manifestations of APAP toxicity by influencing alterations in parameters of renal function (creatinine, urea and uric acid) as well serum electrolytes (Sodium, Potassium and Calcium). DPP treatment further influenced APAP-induced histological lesions by curtailing necrosis and inflammatory changes in the hepatic and renal architecture, respectively. Furthermore, DPP treatment modulated APAP-induced redox imbalance in the hepatic and renal tissue by blunting the increase of malondialdehyde (MDA) as well as decrease of nonprotein sulfhydryls (NP-SH) significantly (p < 0.05) when compared with control. The protective effect of DPP was further confirmed histologically.

**Conclusions:** The present observations point to an hepatorenal protective effects of acute DPP treatment in APAP-intoxicated rats which is underpinned by its robust antioxidant properties.

**Keywords:** Date palm pollen, APAP, nephrotoxic, Hepatotoxic, Silymarin
Introduction
Consumption of plant-derived nutraceuticals and crude drugs in herbal folk medicine is widely believed to confer beneficial effects in liver and kidney diseases. Fruits from the date palm Phoenix dactylifera L. (Arecaceae) which are cultivated in arid regions are widely consumed in a variety of culinary preparations worldwide [1]. Dates are a rich source of dietary fibres, vitamins and minerals. A number of in vitro and in vivo studies have been performed to substantiate their use in folk medicine [1, 2]. Date extracts were shown to possess a myriad of pharmacological properties such as antioxidant [3], anti-inflammatory [4], antiatherogenic [5], hepatoprotective [6], anticancer [6], nephroprotective [7], antimicrobial [8], antiallergic [9], immunostimulatory [10], neuroprotective [11], antifungal [12], antimitogenic [13] and gastrointestinal transition stimulatory activity [14]. Date supplementation was shown to be beneficial in Alzheimer’s disease transgenic mice model [15]. The putative pharmacological effects of dates are attributed to their bioactive constituents with robust antioxidant effects such as tannins [16] and polyphenols which comprise of phenolic acids, hydroxybenzoic and hydroxycinnamic acids, flavonoid glycosides, and proanthocyanidins [17-21]. Other parts of the date palm such as pits were shown to possess robust antibacterial, antifungal and antiviral properties [22, 23]. Date pit extract was further shown to thwart DNA damage and mediate antigenotoxic effects [24].

Previous studies have reported that date palm pollen (DPP) possesses allergenic and antigenic components [25]. Mounting evidence, however, suggests that DPP has a variety of medicinally beneficial effects. Clinical studies have shown that DPP attenuates oral mucositis in patients [26] and shows anti-inflammatory as well as antiproliferative activities in rats [27]. Strikingly, recent studies have reported that DPP extracts mitigate testicular dysfunction triggered by cadmium toxicity and thyroid dysfunction [28] in mice. Along these lines, DPP was shown to influence fertility parameters in adult male rats [29]. Whether DPP administration influences hepatic and/or renal functions, however, remain elusive.

Paracetamol [also known as acetaminophen (APAP)]-induced toxicity in animals is one of the widely used experimental model to investigate the hepatorenal protective activity of plant extract. In the present study, we explored whether and how DPP treatment influences hepatorenal function in rats. To this end, parameters of hepatic and renal function were examined following DPP administration in APAP-intoxicated rats.

Materials and methods
Preparation of dosage form
The DPP grain obtained from a date palm farm of Qassim Area, Saudi Arabia. Any visible contaminants and pieces of spathe were removed; the grain washed with tap water and sieved and dried. Shade dried pollen grain was made into fine powder using mortar and pestle. A 50 g of powder dissolved in 250 ml of warm distilled water (30°C) with constant shaking (magnetic shaker model). The solution was filtered. The water was evaporated and the yield was dissolved in isotonic saline solution was stored in a refrigerator protected from light at 4°C until used.

Chemicals and reagent
All chemicals were obtained from Sigma (Sigma-Aldrich, St. Louis, MO, USA). Crescent and/or Roche Diagnostics kits (AST, ALT, ALP, Total Proteins, albumin, sodium, potassium, Cholesterol, Triglycerides, HDL, LDL, etc.) were used to determine the biochemical parameters estimation on Reflotron Plus Analyzer (Roche Diagnostics GmbH, Mannheim, Germany) and on a Shimadzu UV mini 1240 spectrophotometer (Shimadzu Europe, Milano, Italy) for the other measurement.

Animals and monitoring
Healthy male adult wistar albino rats (150–170 g) were obtained from the experimental animal care center, college of pharmacy, King Saud University (KSU), Riyadh, Saudi Arabia. After a 1-week adaptation period, rats were randomly divided into 5 groups (6 rats/cage) and kept at 22°C ± 2°C, 55% humidity, and 12/12 h –dark cycle. The animals were provided with Purina chow rat diet (UAR-Panlab, Barcelona, Spain) and drinking water ad libitum. All treatment protocols for this study were approved by the Ethics Committee of the Experimental Animal Care Society, KSU, Riyadh.

Pre-treatment and APAP-induced hepatorenal toxicity
Five groups (I–V) of animals were used. Group I served as normal control. Group II received only APAP 1000 mg/kg body weight (b.w) intraperitoneal (i.p) as intoxicated control. Groups III and IV were assigned as test groups. Group III and IV was pre-treated with DPP at doses of 50 and 100 mg/kg b.w. orally consecutive for 14 days, whereas group V was pre-treated with silymarin at a dose of 10 mg/kg b.w. orally, for 14 days. Group I and II animals received a similar volume of vehicle (distilled water) once daily orally. At the 14th day, groups II–V received APAP in tween 80 at a dose of 1000 mg/kg b.w. intraperitoneal (i.p). After 24 h, following APAP challenge, rats were euthanized by ether and then sacrificed and blood was collected by cardiocentesis and serum was obtained by centrifugation at 1000×g for 20 min.
at 4 °C and stored at −70 °C freezer. The liver and kidney were removed for biochemical and histological assessment.

**Analyses of serum hepatic enzymes and lipids**

Serum alanine aminotransferase (ALT) and AST, γ-glutamyl transferase (GGT), alkaline phosphatase (ALP) were determined calorimetrically by methods of Reitman and Frankel [30], Fiala, et al., [31] and King and Armstrong [32] respectively, whereas bilirubin was determined by the method of Stiehl [33]. Serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were measured by the methods of Demacher and Hijamaus [34], Burstein and Scholnick [35] and Foster and Dunn [36] respectively, using Roche kits (Roche Diagnostics GmbH). Low-density lipoprotein cholesterol (LDL-C) and the very low-density lipoprotein-cholesterol (VLDL-C) levels were calculated from the formula: LDL-C = TC-HDL-C-VLDL-C; VLDL-C = TG/5.27.

**Analyses of serum creatinine, urea, uric acid and sodium, potassium and calcium**

Serum creatinine was measured by Jaffe reaction method using CS604 kit (Crescent Diagnostics, Jeddah, Saudi Arabia). Calcium was determined by o-cresolphthalein method described by Gitelman using CE500 kit (Crescent Diagnostics). Urea and uric acid were determined by urease and uricase methods described by Munan, et al. [37] and Fossati, et al., [38] respectively, using Roche kits (Roche Diagnostics GmbH).

**Determination of lipid peroxidation**

A modified method of Utley, et al. [39] was used. The liver (or kidney) was homogenized in 0.15 M KCl at 4 °C and the homogenate (10% w/v, 1 mL) was transferred into a centrifuge tube and incubated at 37 °C for 3 h. Aqueous trichloroacetic acid (TCA, 10%, 1 mL) was then added and the mixture was centrifuged at 800×g for 10 min. The supernatant (1 mL) was mixed with aqueous thiobarbituric acid (TBA, 1 mL, 0.67%) and placed in a boiling water bath for 10 min. The mixture was cooled, diluted with 1 mL distilled water, and absorbance was read at 535 nm. The lipid peroxidation was expressed as malondialdehyde (MDA) in nmol/g wet tissue using a standard curve of MDA dilutions according to the following equation: Absorbance of sample × 72.06 × dilution factor/weight of sample in g × slope of standard curve.

**Estimation of nonprotein sulfhydryl groups**

Hepatic (or renal) nonprotein sulphydryl (NP-SH) groups were measured according to the method of Sedlak and Lindsay [40] after homogenization in ice cold ethylenediaminetetraacetic acid (EDTA, 0.02 M). The homogenate (5 mL) was mixed with distilled water (4 mL) and TCA (50%, 1 mL), shaken for 10 min and then centrifuged. A supernatant (2 mL) was mixed with Tris buffer (4 mL, 0.4 mol/L, pH 8.9) and 5, 5′-dithiobis-(2-nitrobenzoic acid) (DTNB, 0.1 mL) was then added and shaken. Absorbance was measured within 5 min at 412 nm against a reagent blank without homogenate. NP-SH in nmol/g wet tissue is calculated according to the following equation: Corrected Absorbance of sample × dilution factor/weight of sample in g.

**Determination of total protein and albumin**

Serum albumin; and serum and tissue total protein (TP) were estimated according to the method of Doumas by CS600 and CS610 kits (Crescent Diagnostics), respectively. The principle is based on the formation of a blue/violet complex when protein peptide bonds react with Cu (II) ions in alkaline solution (biuret reaction). KNa tartrate and KI Solutions were added as stabilizers. Absorbance was measured at 546 nm and protein was calculated as (Absorbance of sample /Absorbance of standard) × concentration of standard.

**Histopathological evaluation**

The liver and kidney tissue samples were fixed in 10% neutral buffered formalin for 24 h and processed using a VIP tissue processor. The processed tissue were then embedded in paraffin blocks and sections (5 μm thickness) were cut by a rotary microtome (American Optical, Buffalo, NY, USA). Sections were

| **Table 1** Effect of DPP on APAP-intoxicated rats serum marker enzymes | Treatments (n = 6) | Dose (mg/kg) | AST (U/l) | ALT (U/l) | GGT (U/l) | ALP (U/l) |
|---|---|---|---|---|---|---|
| Normal | | | 79.08 ± 4.33 | 30.36 ± 2.38 | 3.80 ± 0.19 | 311.50 ± 6.27 |
| APAP | | 1000 | 296.16 ± 9.22*** | 206.66 ± 16.52*** | 16.75 ± 0.90*** | 604.00 ± 6.08*** |
| DPP + APAP | 50 | 280.83 ± 6.27 | 195.00 ± 7.91 | 15.16 ± 1.07 | 573.83 ± 10.89* |
| DPP + APAP | 100 | 269.66 ± 4.97* | 165.00 ± 3.29* | 13.0 ± 0.54** | 536.16 ± 12.16** |
| Silymarin + APAP | 10 | 165.00 ± 6.82*** | 103.51 ± 6.82*** | 7.53 ± 0.45*** | 355.16 ± 10.98*** |

All values represent mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ANOVA, followed by Dunnett’s multiple comparison test.
stained with hematoxylin and eosin (H & E), and then examined microscopically for pathomorphological changes.

**Statistical analysis**

One-way analysis of variance (ANOVA) was used for data analysis using SPSS software (Statistical Package for the Social Sciences, version 20.0, SPSS Inc., Chicago, IL). All data were expressed as mean ± SEM. Mean values of the groups were compared using the Dunnett’s multiple comparison test. 

**Results**

**Analyses of serum hepatic enzyme profiles**

In a first series of experiments, we explored the effect of DPP on serum markers of hepatic injury. To this end, treatment of rats with APAP significantly increased the levels of the enzymes AST, ALT, GGT and ALP. Pretreatment of rats with DPP significantly and dose-dependently mitigated these effects (Table 1). The effect of DPP was significantly more pronounced at 100 mg/kg. The positive control silibinin, a hepatoprotective agent, significantly curtailed APAP-triggered alterations in serum biomarkers (Table 1).

**Effect of DPP on serum lipoproteins levels**

Next, we analyzed markers of dyslipidemia fostered by hepatic injury. As a result, administration of rats with DPP prior to APAP intoxication dose-dependently abated the changes in serum levels of cholesterol, triglycerides, LDL, VLDL and HDL (Table 2). The positive control silibinin significantly curtailed alterations in serum lipoproteins induced by APAP intoxication (Table 2).

**Determination of renal biochemical parameters**

Further experiments addressed the modulation of extra hepatic biochemical parameters associated with APAP-triggered renal injury. As depicted in Table 3, administration of APAP significantly enhanced the levels of urea, uric acid and creatinine which were significantly and dose-dependently blunted by DPP. The positive control silibinin similarly mitigated APAP-elicited changes in the renal biochemical parameters (Table 4).

**Analyses of electrolytes**

An additional series of experiments examined whether DPP influenced APAP-induced plasma electrolyte imbalance. As shown in Table 4, DPP suspension significantly blunted APAP-induced dysregulation in plasma sodium, potassium and calcium levels, an effect more pronounced at 100 mg/kg DPP. The positive control silibinin significantly curtailed APAP-elicited electrolyte imbalance (Table 4).

**Malondialdehyde, nonprotein-sulfhydryls and total protein determination in liver tissue**

In view of the modulatory effect of DPP on APAP-induced hepatic injury, further experiments explored the underlying mechanism. It was found that the treatment with DPP influences APAP-triggered redox imbalance in the rat hepatic tissue. To this end, we determined hepatic malondialdehyde (MDA), non-protein sulfhydryls (NP-SH) and total protein levels. As shown in Figs. 1, 2 and 3, APAP treatment

### Table 2 Effect of DPP on APAP-intoxicated rats serum lipoproteins of control and experimental rats

| Treatments (n = 6) | Dose (mg/kg) | Cholesterol (mg/dl) | Triglycerides (mg/dl) | HDL (mg/dl) | LDL (mg/dl) | VLDL (mg/dl) |
|-------------------|-------------|---------------------|----------------------|-------------|-------------|--------------|
| Normal            |             | 101.36 ± 4.17       | 81.20 ± 3.02         | 55.91 ± 2.96 | 29.21 ± 5.03 | 16.24 ± 0.60 |
| APAP 1000         |             | 184.66 ± 8.66***    | 150.50 ± 4.95***     | 25.68 ± 1.77*** | 128.88 ± 8.17*** | 30.10 ± 0.99*** |
| DPP + APAP 50     |             | 158.50 ± 5.42*      | 135.16 ± 7.88        | 39.78 ± 1.05*** | 91.68 ± 6.47**   | 27.03 ± 1.57  |
| DPP + APAP 100    |             | 146.66 ± 4.93**     | 107.75 ± 2.51***     | 46.33 ± 1.93*** | 78.78 ± 5.66***  | 21.55 ± 0.50*** |
| Silymarin + APAP 10 |             | 119.33 ± 3.84***    | 99.56 ± 4.85***      | 48.90 ± 2.04*** | 50.52 ± 2.77***  | 19.91 ± 0.97*** |

All values represent mean ± SEM. *p < 0.05; **p < 0.01, ***p < 0.001; ANOVA, followed by Dunnett’s multiple comparison test.

### Table 3 Effect of DPP on APAP-intoxicated rats serum creatinine, urea, uric acid

| Treatments (n = 6) | Dose (mg/kg) | Creatinine (mg/dl) | Urea (mg/dl) | Uric acid (mg/dl) |
|-------------------|-------------|-------------------|--------------|------------------|
| Normal            |             | 1.12 ± 0.11       | 40.85 ± 2.14 | 2.12 ± 0.13     |
| APAP 1000         |             | 3.84 ± 0.11***    | 183.83 ± 5.97*** | 6.66 ± 0.23*** |
| DPP + APAP 50     |             | 2.45 ± 0.18***    | 136.83 ± 6.75*** | 6.11 ± 0.26   |
| DPP + APAP 100    |             | 2.40 ± 0.16***    | 99.53 ± 3.45***  | 4.85 ± 0.28***  |
| Silymarin + APAP 10 |             | 1.82 ± 0.00***    | 81.83 ± 5.28***  | 2.81 ± 0.12***  |

All values represent mean ± SEM. ***p < 0.001; ANOVA, followed by Dunnett’s multiple comparison test.
significantly upregulated hepatic MDA levels, an effect that was significantly and dose-dependently curtailed by DPP and the positive control silymarin. Similarly, DPP treatment counteracted the decrease in hepatic NP-SH and total protein levels induced by APAP treatment. These results suggest the influence of antioxidant effects of DPP in curtailing APAP-induced hepatic damage.

Determination of serum albumin, bilirubin and total protein
Next, we determined the influence of DPP treatment on APAP triggered changes in serum proteins and bilirubin. As depicted in Table 5, APAP treatment significantly enhanced serum bilirubin concentration and significantly reduced serum albumin as well as total protein concentration, an effect significantly mitigated by DPP pretreatment (100 mg/kg) indicating that DPP elicit hepatoprotective effects in vivo. The positive control silymarin similarly blunted APAP triggered alterations in serum bilirubin, albumin and total proteins (Table 5).

Malondialdehyde, nonprotein-sulfhydryls and total protein determination in kidney tissue
To mechanistically corroborate the extrahepatic antioxidant effects of DPP treatment in APAP-treated rats we determined MDA, NP-SH and total protein levels in renal tissue. As shown in Figs. 4, 5 and 6, DPP treatment mitigated APAP triggered upregulation in MDA levels and downregulation in NP-SH and total protein levels, indicating that DPP has antioxidant effects in extra-hepatic renal tissue. The positive control silymarin similarly blunted APAP triggered alterations in renal MDA, NP-SH and total protein levels (Figs. 4, 5 and 6).

Histopathological assessment of rat liver and kidney tissue
Histopathological analyses were carried out to elucidate the impact of DPP treatment on APAP-induced morphological alteration of liver and kidney tissue, depicted in Figs. 7 and 8.

Table 4 Effect of DPP on APAP-intoxicated rats serum sodium, potassium and calcium

| Treatments (n = 6)          | Dose (mg/kg) | Sodium (mg/dl) | Potassium (mg/dl) | Calcium (mg/dl) |
|---------------------------|--------------|----------------|-------------------|-----------------|
| Normal                    |              | 96.45 ± 3.67   | 4.33 ± 0.22       | 4.50 ± 0.20     |
| APAP                      | 1000         | 148.85 ± 2.19**| 12.46 ± 0.62***   | 11.94 ± 1.02*** |
| DPP + APAP                | 50           | 144.68 ± 1.88  | 10.51 ± 0.44*     | 10.61 ± 0.58    |
| DPP + APAP                | 100          | 131.64 ± 3.06**| 8.46 ± 0.33***    | 8.83 ± 0.86*    |
| Silymarin + APAP          | 10           | 115.22 ± 4.20***| 6.61 ± 0.47***    | 5.98 ± 1.11***  |

All values represent mean ± SEM. *p < 0.05; **p < 0.01, ***p < 0.001; ANOVA, followed by Dunnett’s multiple comparison test.

Fig. 1 Liver tissue malondialdehyde (MDA) levels. MDA levels in rats intoxicated with APAP alone and treatment with DPP and Silymarin. All values represent mean ± SEM. ***p < 0.001; ANOVA, followed by Dunnott’s multiple comparison test. a As compared with control group. b As compared with APAP group.
Figure 7 control group showed normal hepatic tissue. APAP only treated group revealed massive focal hepatocytes necrosis, degeneration concomitant with vacuolization. DPP (50 mg/kg) plus APAP treated group showed a mild degeneration and hemorrhage signs. DPP (100 mg/kg) plus APAP treated group showed insignificant changes in far of vacuolization indicated presence of bi-nucleated hepatic cells. Silymarin plus APAP treated animals did not reveal any significant pathological changes in the liver tissues.

Figure 8 control group revealed normal renal tissue. APAP only treated group exhibited sever tissue damage in the form of focal tubular degeneration for both distal and proximal convoluted tubules with tubular dilation. Group DPP (50 mg/kg) plus APAP showed tubular degeneration. Treatment with DPP (100 mg/kg) plus APAP, revealed mild tubular degeneration. Animals revealed Silymarin plus APAP almost showed normal tubular and glomerular tissues architecture.
Discussion

The present study unravels the hitherto unknown, hepatic and renal protective effects of DPP treatment against APAP-elicited toxicity in rats. To this end, DPP treatment mitigated APAP-triggered alterations in biomarkers of hepatic as well as renal function in rats. Our data further shows that DPP treatment curtailed APAP-induced oxidative stress in both hepatic and renal tissue, thus, ameliorating redox-sensitive tissue damage.

APAP is widely used as an antipyretic and analgesic drug and its toxicity encompasses both hepatic and renal failure in humans and experimental animal models [41–43]. As APAP is metabolized in the liver by glucuronidation and sulfation pathways, an overdose triggers a saturation of these pathways resulting in a shift towards CYP450-mediated depletion of hepatic glutathione [44]. Downregulation of hepatic glutathione further elicits mitochondrial dysfunction, generation of reactive oxygen species and tissue necrosis [44]. On the other hand, extra-hepatic toxicity of APAP such as renal injury can occur at lower doses [45]. APAP triggered acute nephrotoxicity is characterized by both functional and morphological evidence of proximal tubular injury which, in turn, is associated with oxidative stress, downregulation of the signaling molecule Bcl-xL, caspase activation, endoplasmic reticulum stress and APAPtotic cell death [46–48]. APAP metabolites were further shown to exert their toxic effects by covalently binding to hepatic and renal DNA [49]. Along those lines, whether DPP extract influences those histological and molecular alterations requires further investigation.

Recent studies of the beneficial effect of some natural compounds against the elevated serum biochemical markers due to APAP-induced hepatorenal toxicity in rats [50–53]. Our results showed DPP caused a significantly diminished the elevated serum hepatic and renal enzymes and lipid profiles. On the other hand our data reveal that DPP treatment confers a robust antioxidant effect on APAP-induced alterations in hepatic and renal malondialdehyde as well as non-protein sulfhydryl concentrations. Mechanistically, redox sensitivity of the protective effects of DPP is possibly mediated by a multitude of its bioactive constituents. DPP were shown to be rich in nutrients such as amino acids, vitamins and minerals [54]. Remarkably,

| Treatments (n = 6) | Dose (mg/kg) | Albumin (g/dl) | Bilirubin (g/dl) | Total Protein (mg/dl) |
|-------------------|-------------|----------------|-----------------|----------------------|
| Normal            |             | 5.741 ± 0.23   | 0.53 ± 0.02     | 5.025 ± 0.19         |
| APAP              | 1000        | 1.55 ± 0.10*** | 2.66 ± 0.11***  | 2.53 ± 0.18***       |
| DPP + APAP        | 50          | 1.77 ± 0.15    | 2.33 ± 0.7      | 2.62 ± 0.15          |
| DPP + APAP        | 100         | 2.23 ± 0.11*** | 2.02 ± 0.06**   | 3.18 ± 0.15          |
| Silymarin + APAP  | 10          | 4.46 ± 0.23*** | 1.12 ± 0.07***  | 3.91 ± 0.33**        |

All values represent mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ANOVA, followed by Dunnett’s multiple comparison test.
DPP were shown to contain phytochemicals such as rutin, flavonoids and phenolic compounds that possess antioxidant activity [54]. By the same token, these phytochemicals were also shown to possess hepatoprotective activities in animal models [42, 54–57]. Intriguingly, DPP treatment was recently shown to attenuate the deleterious effects of cadmium-induced testicular toxicity by inhibiting enhanced oxidative stress [28]. To the best of our knowledge, the hepatorenal protective effects of DPP have not been reported.

Additional putative mechanisms that may contribute to the protective effects of DPP treatment include its previously reported anti-inflammatory potential [27], as APAP toxicity triggers an inflammatory response in the hepatic tissue [58]. Compelling evidence suggests that bioactive constituents of DPP possess anti-inflammatory activities in animal models [59–62]. It is, therefore, tempting to speculate that anti-inflammatory effect of DPP and its constituents [63] further attenuate APAP triggered hepatorenal damage. Taken together, treatment with DPP confers protection against APAP-elicited hepato- and nephrotoxicity in rat, an effect that is mediated, in large part, by its in vivo and in vitro [64, 65] antioxidant and free-radical scavenging properties.
Fig. 7 All sections of liver stained with (H &E) were viewed and evaluated for pathological changes by using a light microscope (Eclipse i80, Nikon, Japan). The required images were taken with Nikon mounted digital camera (OXM 1200C, Nikon, Japan (400X). a- Normal Control b- Received APAP 1000 mg/kg c- DPP (50 mg/kg) + APAP d- DPP (100 mg/kg) + APAP e- Silymarin + APAP
All sections of Kidney stained with (H & E) were viewed and evaluated for pathological changes by using a light microscope (Eclipse i80, Nikon, Japan). The required images were taken with Nikon mounted digital camera (OXM 1200C, Nikon, Japan (400X).  

- **A** - Normal, Control,  
- **B** - Received APAP 1000 mg/kg,  
- **C** - DPP (50 mg/kg) + APAP,  
- **D** - DPP (100 mg/kg) + APAP,  
- **E** - Silymarin + APAP
Conclusions

APAP caused oxidative damage in the hepatic and renal tissue of the experimental animals, and that could be averted by the treatment of DPP. Protective role of DPP could be due to its antioxidant, membrane stabilizing as well as anti-hyperlipidemic actions exerted through modulation of biochemical markers. The wide range of pharmacological effects of DPP may be attributed to the powerful and beneficial ingredients including phenolics, flavonoids, carotenoids, vitamins, minerals, amino acids, fatty acids and organic acids. In addition, results also suggest that DPP might be beneficial for the finding of therapeutic potential against APAP induced hepatic and renal toxicity.

Abbreviations

ALP: Alkaline Phosphatase; ALT: Alanine transaminase; ANOVA: Analysis of variance; APAP: Paracetamol (Acetaminophen); AST: Aspartate transaminase; DPP: Date palm pollen; GGT: γ-Glutamyl transferase; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; MDA: Malondialdehyde; NP-SH: Non-protein sulfhydryls; SIL: Silymarin; TC: Total cholesterol; TG: Triglycerides; TP: Total Protein; VLDL-C: Very low-density lipoprotein-cholesterol

Acknowledgments

The authors would like to thank Mr. Malik Sawood Ahmed for his technical assistance.

Authors’ contributions

This work was carried out in collaboration between all authors. Authors AKAA designed the study; MSAS, supervised and procured the Date Palm Pollen sample, authenticated the material and provided the laboratory facilities. Author SR carried out the experimental and interpreted the data. AAB have participated in statistical analysis. RA collecting literature and typed the manuscript and prepared the Pollen solution. KEI, undertook the histopathological assessment of the tissues. All authors read and approved the final Manuscript.

Funding

None.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The use of laboratory animals were approved by the Ethics Committee of Scientific Research Center, Medical Service Department (MSD), Ministry of Defense, P.O. Box: 22454, Riyadh 11495, Kingdom of Saudi Arabia.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests regarding the publication of this paper.

Author details

1Scientific Research Center, Medical Service Department (MSD), Ministry of Defense, P.O. Box: 22454, Riyadh 11495, Kingdom of Saudi Arabia. 2Department of Pharmacognosy, Medicinal, Aromatic and Poisonous Plants Research Center, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia. 3Department of ENT, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh 11159, Saudi Arabia. 4Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.

Received: 28 August 2019 Accepted: 22 January 2020

References

1. Nalithi TH, Qadir MI, Ali M, Ahmad B, Khan YH, Rehman A. Review: Ajwa date (Phoenix dactylifera) an emerging plant in pharmacological research. Pak J Pharm Sci. 2014;27:607–16.
2. Vayalil PK. Date fruits (Phoenix dactylifera Linn): an emerging medicinal food. Crit Rev Food Sci Nutr. 2012;52:249–71.
3. El-Arem A, Saafi EB, Ghairi F, Thouiri A, Zekri M, Ayed A, et al. Aqueous date fruit extract protects against lipid peroxidation and improves antioxidant status in the liver of rats subchronically exposed to trichloroacetic acid. J Physiol Biochem. 2014a;70:451–64.
4. Borochov-Neori H, Judeinstein S, Greenberg A, Volkova N, Rosenblat M, Aviram M. Antioxidant and antiatherogenic properties of phenolic acid and flavonol fractions of fruits of ‘Amari’ and ‘Hallawi’ date (Phoenix dactylifera L) varieties. J Agric Food Chem. 2015;63:3189–95.
5. Zhang CR, Aldossan SA, Vidyasagar PS, Nair KM, Nair MG. Antioxidant and anti-inflammatory assays confirm bioactive compounds in Ajwa date fruit. J Agric Food Chem. 2013;61:5854–90.
6. Abdelaziz DH, Ali SA. The protective effect of Phoenix dactylifera L seeds against CCl4-induced hepatotoxicity in rats. Ethiop Pharmacol. 2014;15:736–43.
7. El-Arem A, Zekri M, Thouiri A, Saafi EB, Ghairi F, Ayed A, et al. Oxidative damage and alterations in antioxidant enzyme activities in the kidneys of rat exposed to trichloroacetic acid: protective role of date palm fruit. J Physiol Biochem. 2014b;70:297–309.
8. Mahdhi A, Bahi A, Mzah D, Bakhrouf A. Use of mixture design to construct a consortium of date palm (Phoenix dactylifera L) fruit extract and potentially probiotic Bacillus strain to confer protection against vibriosis in Artemia culture. J Sci Food Agric. 2013;93:3850–5.
9. Karasawa K, Otani H. Anti-allergic properties of a matured fruit extract of the date palm tree (Phoenix dactylifera L) in mite-sensitized mice. J Nutr Sci Vitaminol (Tokyo). 2012;58:272–7.
10. Karasawa K, Uzushashi Y, Hirota M, Otani H. A matured fruit extract of date palm tree (Phoenix dactylifera L) stimulates the cellular immune system in mice. J Agric Food Chem. 2011;59:11287–93.
11. Pujari RR, Vyawahare NS, Kagathara VG. Evaluation of antioxidant and neuroprotective effect of date palm (Phoenix dactylifera L) against bilateral common carotid artery occlusion in rats. Indian J Exp Biol. 2011;49:627–33.
12. Boulenouar N, Marouf A, Chetti A. Antifungal activity and phytochemical screening of extracts from Phoenix dactylifera L cultivars. Nat Prod Res. 2011;25:1999–2002.
13. Vayalil PK. Antioxidant and antiinflammatory properties of aqueous extract of date fruit (Phoenix dactylifera L. Arezcoae). J Agric Food Chem. 2002;50:6050–7.
14. Souli A, Sebai H, Ribbi K, Chehimi L, Sakly M, Amri M, et al. Effects of dates pulp extract and palm sap (Phoenix dactylifera L.) on gastrointestinal transit activity in healthy rats. J Med Food. 2014;17:782–6.
15. Subash E, Essa MM, Al-Assiri A, Al-Adawi S, Vaidhna R, Gulmien GI. Effect of dietary supplementation of dates in Alzheimer’s disease APPsw/2576 transgenic mice. J Physiol Biochem. 2014a;70:297–309.
16. Al-Farsi M, Alasalvar C, Morris A, Baron M, Shahidi F. Comparison of antioxidant and anti-atherogenic properties in nine Israeli varieties. J Agric Food Chem. 2013;61:4278–8.
17. Mohamed RM, Fageer AS, Eltayeb MM, Mohamed Ahmed IA. Chemical composition, antioxidant capacity, and mineral extractability of Sudanese date palm (Phoenix dactylifera L) fruits. Food Sci Nutr. 2014;2:478–89.
